The doors are about to be blown off OBD 🚀🎁🐱🏍3 Oct 2023 21:26
Oct 2022: £12 million
The Fundraising will provide working capital to accelerate the commercialization of the EpiSwitch® product line, initially focusing primarily on EpiSwitch® CiRT.
Aug 2023: Another £6 million raised
OBD's next commercial product will be the Prostate Screening EpiSwitch® (PSE) blood test, launched in Q4 2023.
Sept 2023: RNS
Coinciding with Prostate Cancer Awareness month, OBD has brought forward the launch of its highly accurate, 94% precision medicine test to make it immediately available to men being screened for prostate cancer. This includes those who have received an elevated prostate-specific antigen (PSA) result as well as many others where prostate cancer is a clinical concern.
Dr. Phillip Pierorazio, Section Chief of Urology at Penn Presbyterian Medical Center, and Professor of Surgery at the Hospital of University of Pennsylvania. "A more sensitive and specific test would have the potential to increase diagnostic accuracy and address some of the current challenges with prostate cancer screening."
This reminds me of when I started out 40 odd years ago at GSK and they were small. We are about to hit the big time in Pharma land. Enjoy the ride. This is going to be sensational in changing men's lives in the 1st instance with many more indications on the horizon 😉😉😉😉😎😎😎💰💰💰💰🚀🚀🚀🚀🚀